Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
AM-301, marketed as Bentrio™, is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa.
Lead Product(s): AM-301
Therapeutic Area: Immunology Product Name: Bentrio
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Altamira Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.
Lead Product(s): Bentonite,Mono Propylene Glycol,Citric Acid
Therapeutic Area: Immunology Product Name: Bentrio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DKSH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 28, 2022
Details:
RPL554 (ensifentrine) met primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function,significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Verona Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
Ensifentrine (RPL554) is an investigational, first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") that combines bronchodilator and anti-inflammatory activities in one compound.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Verona Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: NTM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neumentum
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in Greater China.
Lead Product(s): AP-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AeroFact
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aerogen
Deal Size: $212.5 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement December 22, 2021
Details:
Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and “PDE4”). Verona Pharma has granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China.
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Verona Pharma
Deal Size: $219.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration June 10, 2021
Details:
The license provides Nuance with exclusive rights to commercialize otenaproxesul in China, Hong Kong, Macau, and Taiwan, representing approximately 10% of the worldwide pharma market.
Lead Product(s): Otenaproxesul
Therapeutic Area: Neurology Product Name: ATB-346
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Antibe Therapeutics
Deal Size: $100.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement February 09, 2021